Another Major Pipeline Setback for Eli Lilly

This episode of The Motley Fool's Market Checkup drills down on the days hottest headlines, including disappointing cancer drug results, a hot new way to fight high cholesterol, and potential problems out of Europe for medical device companies.

In this video, health-care analyst David Williamson discusses today's mixed bag of results for Eli Lilly  (NYSE: LLY  ) investors. Shares of the big pharma traded down after ramucirumab met its primary endpoints in a phase 3 trial for stomach cancer, but not in breast cancer. 

Watch Market Checkup and find out why the surprise failure in treating breast cancer was so important, why the gastric cancer results may not be as good as the headlines, and what Eli Lilly's next moves are for this critical late-stage asset. 

Finding rock-solid dividend stocks
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report, "Secure Your Future With 9 Rock-Solid Dividend Stocks," outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

Follow David on Twitter: @MotleyDavid.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2657450, ~/Articles/ArticleHandler.aspx, 4/17/2014 6:52:23 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement